Literature DB >> 28608409

Neoadjuvant chemoradiotherapy of pancreatic cancer induces a favorable immunogenic tumor microenvironment associated with increased major histocompatibility complex class I-related chain A/B expression.

Takashi Murakami1, Yuki Homma1, Ryusei Matsuyama1, Ryutaro Mori1, Kentaro Miyake1, Yusaku Tanaka1, Kanechika Den1, Yoji Nagashima2, Masatoshi Nakazawa3, Yukihiko Hiroshima1, Michio Ueda1, Kuniya Tanaka1, Robert M Hoffman4, Michael Bouvet5, Itaru Endo1.   

Abstract

BACKGROUND: Damage-associated molecular patterns (DAMPs) are related to immune responses in malignant tumors including tumor-infiltrating lymphocytes (TILs). The aim of the present study was to determine the relationship between expression of components of DAMPs and TILs in pancreatic cancer patients who underwent neoadjuvant chemoradiotherapy (NACRT) versus those who did not.
METHODS: NACRT was administered to 51 patients with borderline-resectable pancreatic cancer and not to 33 patients with resectable pancreatic cancer. Resected specimens were analyzed for the presence of DAMPs, major histocompatibility complex class I-related chain A/B (MICA/B), and CD8+ TILs, CD4+ TILs, and forkhead box P3 positive (Foxp3+ ) TILs. The Treg/TIL ratio was obtained by dividing the number of Foxp3+ TILs, a surrogate for regulatory T cells, by the sum of CD8+ and CD4+ TILs.
RESULTS: Overexpression of calreticulin, Hsp70, and MICA/B were all significantly correlated with NACRT administration. In the NACRT group, high MICA/B expression was associated with a low Treg/TIL ratio, indicating a favorable immunogenic tumor microenvironment. Patients with a lower Treg/TIL ratio had longer survival.
CONCLUSIONS: Overexpression of MICA/B, a component of DAMPs induced by NACRT, may play an important role in acquiring a favorable immune response for pancreatic cancer which contributes to longer survival, suggesting the potential of immunotherapy of this recalcitrant disease, especially for patients with overexpression of DAMPs.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  immunomodulation; neoadjuvant chemoradiotherapy; pancreatic cancer; tumor-associated antigen; tumor-infiltrating lymphocytes

Mesh:

Substances:

Year:  2017        PMID: 28608409     DOI: 10.1002/jso.24681

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  11 in total

1.  Impact of Gemcitabine Plus S1 Neoadjuvant Chemotherapy on Borderline Resectable Perihilar Cholangiocarcinoma.

Authors:  Ryusei Matsuyama; Ryutaro Mori; Yohei Ota; Yuki Homma; Yasuhiro Yabusita; Seigo Hiratani; Takashi Murakami; Yu Sawada; Kentaro Miyake; Yasuhiro Shimizu; Takafumi Kumamoto; Itaru Endo
Journal:  Ann Surg Oncol       Date:  2022-01-07       Impact factor: 5.344

2.  Neoadjuvant therapy alters the collagen architecture of pancreatic cancer tissue via Ephrin-A5.

Authors:  Kosei Nakajima; Yoshinori Ino; Chie Naito; Satoshi Nara; Mari Shimasaki; Utako Ishimoto; Toshimitsu Iwasaki; Noriteru Doi; Minoru Esaki; Yoji Kishi; Kazuaki Shimada; Nobuyoshi Hiraoka
Journal:  Br J Cancer       Date:  2021-11-25       Impact factor: 9.075

3.  Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Borderline Resectable Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgical Resection.

Authors:  Hirokazu Kubo; Takashi Murakami; Ryusei Matsuyama; Yasuhiro Yabushita; Nobuhiro Tsuchiya; Yu Sawada; Yuki Homma; Takafumi Kumamoto; Itaru Endo
Journal:  World J Surg       Date:  2019-12       Impact factor: 3.352

4.  CD11c-Positive Dendritic Cells in Triple-negative Breast Cancer.

Authors:  Heejae Lee; Hee Jin Lee; In Hye Song; Won Seon Bang; Sun-Hee Heo; Gyungyub Gong; In Ah Park
Journal:  In Vivo       Date:  2018 Nov-Dec       Impact factor: 2.155

Review 5.  Biomarkers of Radiotherapy-Induced Immunogenic Cell Death.

Authors:  Rianne D W Vaes; Lizza E L Hendriks; Marc Vooijs; Dirk De Ruysscher
Journal:  Cells       Date:  2021-04-17       Impact factor: 6.600

Review 6.  Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma: Origin, Polarization, Function, and Reprogramming.

Authors:  Sen Yang; Qiaofei Liu; Quan Liao
Journal:  Front Cell Dev Biol       Date:  2021-01-11

7.  The immunological impact of preoperative chemoradiotherapy on the tumor microenvironment of pancreatic cancer.

Authors:  Satoshi Okubo; Toshihiro Suzuki; Masayoshi Hioki; Yasuhiro Shimizu; Hirochika Toyama; Soichiro Morinaga; Naoto Gotohda; Katsuhiko Uesaka; Genichiro Ishii; Shinichiro Takahashi; Motohiro Kojima
Journal:  Cancer Sci       Date:  2021-05-19       Impact factor: 6.716

Review 8.  Immunogenic Cell Death Induction by Ionizing Radiation.

Authors:  Mengqin Zhu; Mengdie Yang; Jiajia Zhang; Yuzhen Yin; Xin Fan; Yu Zhang; Shanshan Qin; Han Zhang; Fei Yu
Journal:  Front Immunol       Date:  2021-08-20       Impact factor: 7.561

9.  Hypoxia-reprogrammed regulatory group 2 innate lymphoid cells promote immunosuppression in pancreatic cancer.

Authors:  Longyun Ye; Kaizhou Jin; Zhenyu Liao; Zhiwen Xiao; Huaxiang Xu; Xuan Lin; Hao Li; Tianjiao Li; Wuhu Zhang; Xuan Han; Wenquan Wang; Heli Gao; Liang Liu; Weiding Wu; Xianjun Yu
Journal:  EBioMedicine       Date:  2022-04-25       Impact factor: 11.205

10.  The Prognostic Index Independently Predicts Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Resection.

Authors:  Elisabeth S Gruber; Gerd Jomrich; Alexandra Kaider; Michael Gnant; Klaus Sahora; Martin Schindl
Journal:  Ann Surg Oncol       Date:  2020-01-03       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.